|
1. |
Role of Hyperthermic Perfusion in the Treatment of Limb Osteogenic Sarcoma |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 1-5
R. Cavaliere,
F. Di Filippo,
F.S. Santori,
L. Piarulli,
S. Carlini,
A. Calabrò,
M. Pagliarin,
F. Cavaliere,
P. Cerulli,
G. Monticelli,
Preview
|
PDF (2297KB)
|
|
摘要:
The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5- and 10-year survival rate of 25.5% was obtained. When amputation was systematically associated to HP (12 patients), a 5- and 10-year survival rate of 50.9% was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5- and 10-year actuarial rates rose to 71.4 and 65%, respectively, with a 5-year disease-free survival rate of 67.4%. Fifteen patients were treated with HAP followed by an ‘en bloc’ resection and bone reconstruction. The 5- and 10-year actuarial survival rate obtained was 63.5% with a 5-year disease-free survival rate of 53.6%. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarc
ISSN:0030-2414
DOI:10.1159/000226433
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
2. |
Epirubicin Treatment of Advanced Breast Carcinoma with the Weekly Low-Dose Regimen |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 6-12
G. Beretta,
C. Locatelli,
D. Tabiadon,
R. Labianca,
P. Fraschini,
G. Luporini,
Preview
|
PDF (1545KB)
|
|
摘要:
Authors describe the results obtained with weekly low-dose (20 or 30 mg/total) of intravenous bolus epirubicin, used as second line chemotherapy, after CMF, in 29 advanced breast carcinoma patients. 29% objective response rate (1 complete + 6 partial responses) has been observed in 24 evaluable patients, with median response duration of 4 months (range 1–7+). The discrete response rate and the minimal incidence of side effects call for further studies and more extensive evaluation of epirubicin given alone or in combination through this new treatment schedul
ISSN:0030-2414
DOI:10.1159/000226434
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
3. |
Glucocorticoid Receptors Predict Response to Combination Chemotherapy in Patients with Acute Lymphoblastic Leukemia |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 13-16
Stefano Iacobelli,
Paolo Marchetti,
Giulio De Rossi,
Franco Mandelli,
Nicola Gentiloni,
Preview
|
PDF (1224KB)
|
|
摘要:
Glucocorticoid receptor levels were quantified in leukemic blasts from peripheral blood of 86 patients with acute lymphoblastic leukemia. Subsequent achievement of complete remission correlated with high receptor levels. Forty-seven of 50 patients with leukemic cells containing more than 6,000 receptor sites and 22 of 36 patients with cells containing less than 6,000 receptor sites achieved remission. The study of glucocorticoid receptors in leukemic cells may predict response to combination chemotherapy in acute lymphoblastic leukemia patients.
ISSN:0030-2414
DOI:10.1159/000226435
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
4. |
In vitro and in vivo Enhancement of Vincristine Antitumor Activity on B16 Melanoma Cells by Calcium Antagonist Flunarizine |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 17-23
Alberto Bellelli,
Claudia Camboni,
Giovanna de Luca,
Mario Materazzi,
Manlio Mattioni,
Maria Luisa Sezzi,
Luciano Bellelli,
Preview
|
PDF (1583KB)
|
|
摘要:
Flunarizine, a calcium antagonist commonly employed in therapy for vascular diseases, enhances the in vitro and in vivo antitumor activity of vincristine on B16 melanoma cells. In the presence of flunarizine higher intracellular levels of vincristine were observed in vitro and for a longer time. B16 melanoma bearing mice treated with both the drugs presented a median survival time that was significantly longer than that of the controls. The possible mechanism of the enhancement is herein discussed.
ISSN:0030-2414
DOI:10.1159/000226436
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
5. |
Relationship between Flow Cytometric Parameters, Steroid Receptors, and Menopausal Status in Breast Cancers |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 24-29
Henry M. Abandowitz,
Kim T. Ow,
Debra Hardy,
David D. Keightley,
Gordon A. Sarfaty,
Allan R. Nash,
Preview
|
PDF (2517KB)
|
|
摘要:
Of 163 human breast cancers examined, 68% contained detectable aneuploid populations, whilst 32% had apparently normal DNA distributions. A slightly higher incidence of aneuploidy was observed in pre-menopausal patients (83%) than in post-menopausal patients (66%). Also, pre-menopausal patients had slightly higher proportions of S-phase or cycling (S + G2 + M) cells. Estradiol receptor negative (ER –) tumours from post-menopausal patients were found to have the lowest incidence of aneuploidy (59%) and ER– tumours from pre-menopausal patients the highest (91%). There were no significant differences in the proportions of cycling nuclei when receptor status and menopausal status were considered. A weak relationship is shown to exist between flow cytometric data and two common prognostic indicators of breast cancer, namely receptor status and menopausal sta
ISSN:0030-2414
DOI:10.1159/000226437
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
6. |
Aromatisation of Androstenedione by Human Breast Cancer Tissue: Correlation with Hormone Receptor Activity and Possible Biologic Significance |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 30-33
W.R. Bezwoda,
N. Mansoor,
R. Dansey,
J.D. Esser,
Preview
|
PDF (1847KB)
|
|
摘要:
The conversion of 1β [3H] androstenedione to estrone in the presence of NADPH by breast cancer homogenates was assessed in tumors from 35 subjects together with estrogen and progesterone receptor concentration. Breast cancers from post menopausal women had significantly higher aromatase activity than those from premenopausal women. Although in many instances the local production of estrogens was sufficient to the capable of exerting a biologic effect, there was, however, no correlation with tumor estrogen or progesterone receptor content. Further studies of the biological significance of tumor aromatisation will depend on direct observation of tumor aromatase and response to suitable doses of aromatase inhibitors
ISSN:0030-2414
DOI:10.1159/000226438
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
7. |
Reduction ofcis-Dichlorodiammineplatinum(II) Caused Nephrotoxicity by Indazolone Carboxilic Acid |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 34-37
M. Radačić,
M. Boranić,
Ðurđa Škarić,
V. Škarić,
Helena Mihalić,
Vesna Gajšak,
J. Jerčić,
P. Lelieveld,
Preview
|
PDF (1707KB)
|
|
摘要:
To reduce the nephrotoxicity of cis-dichlorodiammineplatinum (cis-DDP) we have used tetrahydroindazolonedicarboxylic acid (HIDA) in doses of 200, 100 or 50 mg/kg 4, 2 and 1 h before or 1, 2 and 4 h after cis-DDP treatment (10 mg/kg). At any dose, given 2 or 1 h before or 1 h after cis-DDP, HIDA reduced the kidney damage as judged by the blood urea nitrogen (BUN) levels in blood. No protective effect was seen when HIDA was given 4 h before cis-DDP injection. Studies in vitro on L1210 cells have revealed that HIDA does not directly interact with cis-DDP.
ISSN:0030-2414
DOI:10.1159/000226439
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
8. |
Peripheral Blood Lymphocyte Subsets in Nasopharyngeal Carcinoma |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 38-41
C.S. Ng,
W. Chick,
S.Y. Tsao,
S.K. O,
J.Y. Sung,
J.C.K. Lee,
W. Shiu,
P.N.M. Cheng,
W.M.C. Martin,
Preview
|
PDF (2046KB)
|
|
摘要:
Peripheral blood lymphocyte subsets were studied in 29 untreated Chinese nasopharyngeal carcinoma (NPC) patients and 20 normal controls of similar age range and sex ratio with indirect immunofluorescence using monoclonal antibodies. The percentage T lymphocyte (T11) count, percentage and absolute T helper (T4) lymphocyte counts and the T helper/T suppressor-cytotoxic cell ratio (T4/T8) were significantly lower, while the percentage and absolute T8 counts were significantly higher in NPC patients. Concerning B lymphocytes, B1 cell count was normal while B4 cell count (B lymphocytes including early B lymphocytes) was significantly lower in NPC patients. These various lymphocyte subset changes were not related to the clinical stage or to Epstein-Barr viral IgA viral capsid antibodies and IgA early antibodies. The pathogenetic and prognostic significance of peripheral blood lymphocyte changes in NPC requires further investigation.
ISSN:0030-2414
DOI:10.1159/000226440
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
9. |
In vivo Effect of Didemnin B on Two Tumors of the Rat |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 42-46
Vincenzo Fimiani,
Preview
|
PDF (1874KB)
|
|
摘要:
Didemnin B administered at a dose of 0.06 mg/kg, highest nontoxic dose for the rat, shows a high antitumor activity against Yoshida ascites tumor only after intraperitoneal injection of the drug; supplied by other routes both against T8 sarcoma of Guérin and Yoshida ascites tumor is ineffective
ISSN:0030-2414
DOI:10.1159/000226441
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
10. |
Restoration of Doxorubicin Responsiveness in Doxorubicin-Resistant P388 Murine Leukaemia Cells by Dipyrone |
|
Oncology,
Volume 44,
Issue 1,
1987,
Page 47-50
Manik P. Chitnis,
Narayana S. Kamath,
Preview
|
PDF (2018KB)
|
|
摘要:
The effect of dipyrone along with doxorubicin and mitoxantrone was studied alone and in combination on the 3H-thymidine (3H-TdR) incorporation in P388 leukaemia sensitive (P388/S) and resistant (P388/ADR) to doxorubicin. Dipyrone 10––4M demonstrated minimal inhibitory effect on DNA biosynthesis in both the sensitive and resistant cells. Doxorubicin and mitoxantrone at equimolar concentrations, indicated time and dose-dependent inhibition in 3H-TdR incorporation in the sensitive cells. The inhibition was more at the higher drug concentrations at 4 h drug exposure. Mitoxantrone showed cross-resistance in P388/ADR compared to P388/S. Both the drugs along with 10––4M dipyrone in the incubating medium revealed synergistic inhibitory activity in P388/S and P388/ADR. Observations indicate circumvention of doxorubicin and mitoxantrone resistance in P388/ADR by d
ISSN:0030-2414
DOI:10.1159/000226442
出版商:S. Karger AG
年代:1987
数据来源: Karger
|
|